BioStock: Immunicum’s strategy for fighting tumour recurrence

Tumour recurrence is the underlying cause of the majority of cancer deaths worldwide. It is thus considered one of the most pressing challenges within the oncology field. Swedish immuno-oncology company Immunicum is addressing this challenge with relapse vaccine candidate DCP-001, which is currently in phase II clinical stage. BioStock takes a closer look.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/immunicums-strategy-for-fighting-tumour-recurrence/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se